Versions
- 2026-06-12 (2)
- 2026-06-06 (1)
Keywords
SGLT2 Inhibitors
meta-analysis
randomised trials
How to Cite
Abstract
Patients with type 2 diabetes or recent worsening heart failure remain at high cardiovascular risk; does the use of Sotagliflozin across both settings help to reduce this? This living meta-analysis included 11,806 participants from the randomized placebo-controlled SCORED and SOLOIST-WHF trials. Hazard ratios were combined using inverse-variance fixed-effect modelling on the logarithmic scale. The pooled estimate for the primary cardiovascular composite outcome was 0.72 (95% CI 0.63–0.82) without observed heterogeneity (I² = 0%). Both trials individually supported Sotagliflozin, with SCORED reporting a hazard ratio of 0.74 and SOLOIST-WHF reporting 0.67. These findings suggest that Sotagliflozin lowers cardiovascular event risk by nearly twenty-eight percent in chronic diabetes and recently decompensated heart failure populations. Interpretation should consider possible variation during post-discharge treatment periods, the early termination of SOLOIST-WHF as well as the need for continued surveillance of ketoacidosis ri
References
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129-139. PMID 33200891. doi:10.1056/NEJMoa2030186.
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-128. PMID 33200892. doi:10.1056/NEJMoa2030183.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71. PMID 33782057.
Higgins JPT, Thomas J, Chandler J, et al, editors. Cochrane Handbook for Systematic Reviews of Interventions, version 6.4. Cochrane; 2023. www.training.cochrane.org/handbook.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Sara Ahmed Ahmed, Mahmood Ahmad